PL2054040T3 - Sposób wytwarzania stałych dyspersji midostauryny - Google Patents

Sposób wytwarzania stałych dyspersji midostauryny

Info

Publication number
PL2054040T3
PL2054040T3 PL07811314T PL07811314T PL2054040T3 PL 2054040 T3 PL2054040 T3 PL 2054040T3 PL 07811314 T PL07811314 T PL 07811314T PL 07811314 T PL07811314 T PL 07811314T PL 2054040 T3 PL2054040 T3 PL 2054040T3
Authority
PL
Poland
Prior art keywords
solid dispersions
midostaurin
making solid
highly crystalline
compounds
Prior art date
Application number
PL07811314T
Other languages
English (en)
Polish (pl)
Inventor
Indrajit Ghosh
Jennifer Snyder
Wei-Qin Tong
Sudha Vippagunta
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2054040T3 publication Critical patent/PL2054040T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL07811314T 2006-08-16 2007-08-14 Sposób wytwarzania stałych dyspersji midostauryny PL2054040T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82255606P 2006-08-16 2006-08-16
PCT/US2007/017960 WO2008021347A2 (en) 2006-08-16 2007-08-14 Method for making solid dispersions of highly crystalline therapeutic compounds
EP07811314A EP2054040B1 (en) 2006-08-16 2007-08-14 Method for making solid dispersions of midostaurin

Publications (1)

Publication Number Publication Date
PL2054040T3 true PL2054040T3 (pl) 2011-09-30

Family

ID=38657762

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07811314T PL2054040T3 (pl) 2006-08-16 2007-08-14 Sposób wytwarzania stałych dyspersji midostauryny

Country Status (16)

Country Link
US (2) US20100038816A1 (https=)
EP (1) EP2054040B1 (https=)
JP (1) JP5546860B2 (https=)
KR (1) KR101462693B1 (https=)
CN (1) CN101516339B (https=)
AT (1) ATE503484T1 (https=)
AU (1) AU2007284615B2 (https=)
BR (1) BRPI0714963A2 (https=)
CA (1) CA2660086C (https=)
DE (1) DE602007013567D1 (https=)
ES (1) ES2363725T3 (https=)
MX (1) MX2009001636A (https=)
PL (1) PL2054040T3 (https=)
PT (1) PT2054040E (https=)
RU (1) RU2454220C2 (https=)
WO (1) WO2008021347A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
MX2010011962A (es) * 2008-04-30 2010-11-30 Novartis Ag Proceso continuo para hacer composiciones farmaceuticas.
EP2327706A1 (en) 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN102525879B (zh) * 2010-12-31 2015-01-21 正大天晴药业集团股份有限公司 制备阿瑞匹坦固体分散组合物的方法
BR112016021739B1 (pt) * 2014-03-25 2021-11-03 Genentech, Inc Método para preparar um poloxâmero para uso em um meio de cultura de célula
CN107001322B (zh) 2014-12-18 2020-07-28 默沙东公司 用于药物制剂的组合物
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
CN108024939B (zh) 2015-08-20 2024-06-07 联合利华知识产权控股有限公司 包封的内酰胺
ES2758300T3 (es) 2015-08-20 2020-05-05 Unilever Nv Solubilidad de lactama mejorada
EP3337451B1 (en) 2015-08-20 2018-12-26 Unilever PLC Improved lactam solubility
CN107848968B (zh) 2015-08-20 2021-06-18 荷兰联合利华有限公司 从乙醛酸制备内酰胺的方法
WO2017029093A1 (en) 2015-08-20 2017-02-23 Unilever Plc Improved lactam solubility
CN107920976A (zh) 2015-08-20 2018-04-17 荷兰联合利华有限公司 改善的内酰胺溶解度
BR112018003082B1 (pt) * 2015-08-20 2021-12-14 Unilever Ip Holdings B.V. Lactama em uma dispersão sólida, método de produção de uma composição compreendendo uma lactama e método de formação de lactama em uma dispersão sólida
JP7021182B2 (ja) * 2016-03-24 2022-02-16 ロケート・バイオ・リミテッド 足場材料、方法および使用
MX383740B (es) * 2016-05-13 2025-03-14 Merck Patent Gmbh Composición de extrusión fundida en caliente que usa un excipiente compresible directo como plastificante.
CN111615389A (zh) 2018-02-01 2020-09-01 科尔沃斯制药股份有限公司 药物调配物
EP3520782A3 (en) * 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
CN113573712A (zh) 2019-02-18 2021-10-29 斯莱班克制药有限责任公司 尼洛替尼的药物组合物
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN114796149A (zh) * 2022-04-27 2022-07-29 苏州中化药品工业有限公司 一种高生物利用度的双醋瑞因胶囊剂及其制备方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5837714A (en) * 1997-03-03 1998-11-17 Sanofi Solid pharmaceutical dispersions
ATE232087T1 (de) * 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
EP1372611B1 (en) 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
HU229938B1 (en) * 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
US6756381B2 (en) * 2002-02-21 2004-06-29 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
US7498309B2 (en) * 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
CN102127057A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
US20050288481A1 (en) * 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
MX2007002415A (es) * 2004-08-31 2007-04-23 Novartis Ag Uso de midostaurina para el tratamiento de tumores estromales gastrointestinales.
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JO2897B1 (en) * 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
WO2007068615A2 (en) * 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation
BRPI0622054B8 (pt) * 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US8258137B2 (en) * 2008-01-29 2012-09-04 Katholieke Universiteit Leuven Process for release of biologically active species from mesoporous oxide systems
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
CN107898791A (zh) * 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
EP2618846A1 (en) * 2010-09-24 2013-07-31 Mallinckrodt LLC Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
US9295673B2 (en) * 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

Also Published As

Publication number Publication date
MX2009001636A (es) 2009-02-23
WO2008021347A3 (en) 2008-08-07
WO2008021347A2 (en) 2008-02-21
CN101516339B (zh) 2012-06-13
CA2660086A1 (en) 2008-02-21
EP2054040B1 (en) 2011-03-30
ES2363725T3 (es) 2011-08-12
DE602007013567D1 (de) 2011-05-12
US8641948B2 (en) 2014-02-04
KR20090042961A (ko) 2009-05-04
PT2054040E (pt) 2011-06-30
US20120190667A1 (en) 2012-07-26
JP2010500411A (ja) 2010-01-07
AU2007284615B2 (en) 2011-10-27
RU2454220C2 (ru) 2012-06-27
BRPI0714963A2 (pt) 2013-07-30
ATE503484T1 (de) 2011-04-15
AU2007284615A1 (en) 2008-02-21
RU2009109357A (ru) 2010-09-27
KR101462693B1 (ko) 2014-11-17
US20100038816A1 (en) 2010-02-18
CA2660086C (en) 2014-09-16
CN101516339A (zh) 2009-08-26
JP5546860B2 (ja) 2014-07-09
EP2054040A2 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
PT2054040E (pt) Método para produzir dispersões sólidas de compostos terapêuticos altamente cristalinos
PL1993985T3 (pl) Sposób wytwarzania 1,2-propanodiolu
TWI371461B (en) Polyvinyl alcohol film, and process for producing the same
IL221579A (en) Foams, pre-blended compositions, and inflating materials containing fluorinated olefins and foam preparation methods
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
ZA200810228B (en) Thermoplastic articles and processes for making the same using an improved masterbatch
EP1873847A4 (en) CATHODE ACTIVE MATERIAL AND METHOD OF MANUFACTURING THE SAME
EP2028222A4 (en) ORIENTED POLYMER FILM OF NORBORNENE COMPOUND ADDITION ONLY, PROCESS FOR PRODUCTION THEREOF, AND USE THEREOF
IL193155A0 (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
GB2433835B (en) Organic thin film transistor and method for manufacturing the same
EP1916241A4 (en) CRYSTAL OF A PHENYLALANINE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE
PL1873158T3 (pl) Kryształy pochodnej morfinanu i sposoby ich wytwarzania
GB0915454D0 (en) Novel benzothiazole and benzoxazole linked pyrrolo (2,1-C) (1,4) benzodiazepine hybrids as novel antitumour agents and process for the preparation thereof
IL185335A0 (en) Process for the preparation of substituted benzoxazole compounds
HRP20130860T1 (en) Naphthyridine derivative monohydrate and method for producing the same
EP1834624A4 (en) MEDICAL COMPOSITION AND MANUFACTURING METHOD THEREFOR
EP1833955B8 (en) Plasticized article for treating the skin
FI20041610A0 (fi) Menetelmä tuotantoyksikössä käytettävän rehun tuotannon ohjaamiseksi
ZA200801600B (en) Chemical process for the preparation of benzoxazole derivatives used as pesiticides
ZA200903936B (en) Method for the production of an agent against an infectuous disease
PL378550A1 (pl) Sposób wytwarzania 6ß, 14 α-dihydroksypregnan-4-en-3, 20-dionu
PL378552A1 (pl) Sposób wytwarzania 7 α-hydroksyandrost-4-en-3,17-dionu
PL373983A1 (pl) Kompozycja elastotermoplastyczna, sposób wytwarzania kompozycji elastotermoplastycznej oraz wytworzony z tej kompozycji elastomer termoplastyczny
AU2005904547A0 (en) Process for the treatment of an organic material
HK1110594A (en) Process for the preparation of substituted benzoxazole compounds